September 19, 2024
“Apple is in discussions with JPMorgan Chase for the bank to take over the tech giant’s flagship credit card program from Goldman Sachs, a person with knowledge of the negotiations said. The discussions are still early and could falter, and… Continue Reading…
August 8, 2024
https://www.barrons.com/articles/fed-goldman-recession-rates-16bf36fc Article is behind a paywall so I’ll make a few comments instead. First of all we are already in a recession. The government altered the definition in order to avoid stating the obvious. Second, by the time mainstream media… Continue Reading…
July 31, 2024
“…RegenXBio (RGNX) The first Goldman pick we’ll look at is RegenXBio, a gene therapy company specializing in single-dose treatments for severe diseases with few or no existing therapies…. Choi rates RGNX a Buy along with a $38 price target. This… Continue Reading…
April 18, 2023
“Goldman Sachs posted first-quarter profit on Tuesday that missed analysts’ expectations for revenue after taking a $470 million hit tied to the sale of consumer loans. Here’s what the company reported: The bank said earnings fell 18% to $3.23 billion,… Continue Reading…
August 31, 2022
“…U.K. inflation could soar above 22% next year if energy prices continue their upward spiral, U.S. investment bank Goldman Sachs warned. In a research note dated Monday, Goldman said headline inflation could peak at 22.4% and gross domestic product could drop by… Continue Reading…
February 23, 2022
“Hydrogen has an important role to play in any transition to net-zero and its generation could develop into a market worth over $1 trillion a year, according to Goldman Sachs. “If we want to go to net-zero we can’t do it… Continue Reading…
October 18, 2021
“…The investment bank projects that home prices — already at record highs — will grow another 16% by the end of 2022. Despite price increases of 20% over the past year, the analysts at Goldman Sachs suggest that homes remain “relatively affordable” thanks to historically… Continue Reading…
September 16, 2021
“Dole Plc (DOLE)… Overall, the recent analyst reviews on DOLE, breaking down to 3 Buys, 1 Hold, and 1 Sell, give the stock a Moderate Buy consensus rating. Shares are priced at $14.87 and the average price target of $19.60 implies… Continue Reading…
July 19, 2021
“Ambrx Biopharma (AMAM)… This new biopharma stock has a Strong Buy rating from the analyst consensus, based on 3 positive reviews so far. The shares are priced at $19.56 and their $39.50 average target suggests room for an upside of 101%… Continue Reading…
Recent Comments